Gilead is reportedly looking to acquire Arrowhead Research, primarily because of the latter company’s hepatitis B pipeline consisting of experimental drugs such as ARC-520
Gilead Sciences, Inc. (NASDAQ:GILD) is eyeing Arrowhead Research Corp (NASDAQ:ARWR) for an acquisition, sending a strong signal to the market about the company’s resilience to the recent thrashing by buying out a small cap, as per rumors on the Street.
California-based Arrowhead has many promising products in its pipeline, including ARC-520, an experimental drug that is being tested for its efficacy in treating chronic hepatitis B. The biopharmaceutical is also working on an anti-obesity drug candidate.
Share This Page